John Libbey Eurotext

European Journal of Dermatology

A case of malignant melanoma that developed multiple metastases after switching from interferon-beta to pegylated interferon-alpha-2b as adjuvant therapy Ahead of print

Figures

  • Figure 1
Authors
1 Gene Expression and Regulation Program, The Wistar Institute, Philadelphia, PA, USA
2 Division of Dermatology, Department of Internal Related, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, Japan
3 Division of Dermatology, Tohoku Medical and Pharmaceutical University, 1-12-1 Fukumuro, Miyagino-ku, Sendai, Japan

Although therapeutic strategies for melanoma have advanced, melanoma remains incurable owing to frequent recurrence and metastasis, requiring effective adjuvant therapy [1].Adjuvant therapy with interferon (IFN)-α-2b improves recurrence-free and overall survival [1]. Pegylated (PEG)-IFN-α-2b, an IFN molecule covalently bound to polyethylene glycol, can maintain longer sustained effects with less frequent injection than unpegylated-IFN-α-2b, and has been utilized as a global standard adjuvant therapy [...]